NO20061415L - Kinazolinderivater - Google Patents
KinazolinderivaterInfo
- Publication number
- NO20061415L NO20061415L NO20061415A NO20061415A NO20061415L NO 20061415 L NO20061415 L NO 20061415L NO 20061415 A NO20061415 A NO 20061415A NO 20061415 A NO20061415 A NO 20061415A NO 20061415 L NO20061415 L NO 20061415L
- Authority
- NO
- Norway
- Prior art keywords
- quinazoline
- medicament
- inhibition
- prevention
- manufacture
- Prior art date
Links
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 108060006698 EGF receptor Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0321621A GB0321621D0 (en) | 2003-09-16 | 2003-09-16 | Quinazoline derivatives |
| GB0322458A GB0322458D0 (en) | 2003-09-25 | 2003-09-25 | Quinazoline derivatives |
| PCT/GB2004/003911 WO2005026156A1 (fr) | 2003-09-16 | 2004-09-13 | Derives de quinazoline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20061415L true NO20061415L (no) | 2006-04-07 |
Family
ID=34315441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20061415A NO20061415L (no) | 2003-09-16 | 2006-03-28 | Kinazolinderivater |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20080234263A1 (fr) |
| EP (1) | EP1664030A1 (fr) |
| AR (1) | AR045753A1 (fr) |
| AU (1) | AU2004272345A1 (fr) |
| CA (1) | CA2541100A1 (fr) |
| IL (1) | IL174390A0 (fr) |
| MX (1) | MXPA06003161A (fr) |
| NO (1) | NO20061415L (fr) |
| TW (1) | TW200526636A (fr) |
| UY (1) | UY28519A1 (fr) |
| WO (1) | WO2005026156A1 (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE395346T1 (de) | 2003-09-16 | 2008-05-15 | Astrazeneca Ab | Chinazolinderivate als tyrosinkinaseinhibitoren |
| GB0322409D0 (en) * | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
| GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| EP1694686A1 (fr) | 2003-12-19 | 2006-08-30 | Takeda San Diego, Inc. | Inhibiteurs de kinase |
| DE602005010824D1 (de) | 2004-02-03 | 2008-12-18 | Astrazeneca Ab | Chinazolinderivate |
| WO2006023931A2 (fr) | 2004-08-18 | 2006-03-02 | Takeda San Diego, Inc. | Inhibiteurs de kinase |
| EP1812439B2 (fr) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Inhibiteurs de kinase |
| ATE501148T1 (de) * | 2004-12-14 | 2011-03-15 | Astrazeneca Ab | Pyrazolopyrimidinverbindungen als antitumormittel |
| EP1957468A2 (fr) * | 2005-09-06 | 2008-08-20 | T.K. Signal Ltd. | Derives polyalkylene-glycol d'inhibiteurs irreversibles de la tyrosine kinase du recepteur du facteur de croissance epidermique |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| TWI403320B (zh) * | 2005-12-16 | 2013-08-01 | Infinity Discovery Inc | 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法 |
| SG158147A1 (en) | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
| FR2933700B1 (fr) * | 2008-07-08 | 2010-07-30 | Sanofi Aventis | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique |
| FR2952934B1 (fr) | 2009-11-23 | 2012-06-22 | Sanofi Aventis | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique |
| DK2655388T3 (en) | 2010-12-23 | 2016-09-19 | Alectos Therapeutics Inc | Selective glykosidaseinhibitorer and uses thereof |
| WO2012129651A1 (fr) | 2011-03-31 | 2012-10-04 | Alectos Therapeutics Inc. | Inhibiteurs sélectifs de glycosidases et leurs utilisations |
| WO2013000086A1 (fr) | 2011-06-27 | 2013-01-03 | Alectos Therapeutics Inc. | Inhibiteurs de glycosidases sélectifs et leurs utilisations |
| WO2014032185A1 (fr) | 2012-08-31 | 2014-03-06 | Alectos Therapeutics Inc. | Inhibiteurs de glycosidases et leurs utilisations |
| WO2014032188A1 (fr) * | 2012-08-31 | 2014-03-06 | Alectos Therapeutics Inc. | Inhibiteurs des glycosidases et leurs utilisations |
| WO2014032184A1 (fr) * | 2012-08-31 | 2014-03-06 | Alectos Therapeutics Inc. | Inhibiteurs de glycosidases et leurs utilisations |
| WO2014067003A1 (fr) | 2012-10-31 | 2014-05-08 | Alectos Therapeutics Inc. | Inhibiteurs de glycosidases et applications associées |
| US9977024B2 (en) | 2012-12-09 | 2018-05-22 | The Scripps Research Institute | Targeted covalent probes and inhibitors of proteins containing redox-sensitive cysteines |
| EP2964638B1 (fr) | 2013-03-06 | 2017-08-09 | Astrazeneca AB | Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr) |
| WO2017122205A1 (fr) | 2016-01-13 | 2017-07-20 | Hadasit Medical Research Services And Development Ltd. | Analogues radiomarqués de l'erlotinib et leurs utilisations |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4335127A (en) * | 1979-01-08 | 1982-06-15 | Janssen Pharmaceutica, N.V. | Piperidinylalkyl quinazoline compounds, composition and method of use |
| US4921863A (en) * | 1988-02-17 | 1990-05-01 | Eisai Co., Ltd. | Cyclic amine derivatives |
| GB9300059D0 (en) * | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| GB9607729D0 (en) * | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
| EP0837063A1 (fr) * | 1996-10-17 | 1998-04-22 | Pfizer Inc. | Dérivés de 4-aminoquinazoline |
| GB9800575D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| US6297258B1 (en) * | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| CA2361174C (fr) * | 1999-02-27 | 2009-10-27 | Boehringer Ingelheim Pharma Kg | 4-aminoquinazoline et derives de quinazoline ayant un effet inhibiteur sur la transduction du signal assiste par les tyrosine-kinases |
| DE19911509A1 (de) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| HK1044769B (zh) * | 1999-06-21 | 2005-02-25 | 贝林格尔英格海姆法玛两合公司 | 雙環雜環化合物，含有該化合物的藥物組合物，該化合物的用途及其製備方法 |
| US20020082270A1 (en) * | 2000-08-26 | 2002-06-27 | Frank Himmelsbach | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
| US6617329B2 (en) * | 2000-08-26 | 2003-09-09 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines and their use as medicaments |
| DE10042059A1 (de) * | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US6562319B2 (en) * | 2001-03-12 | 2003-05-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy |
| EP1396488A1 (fr) * | 2001-05-23 | 2004-03-10 | Mitsubishi Pharma Corporation | Compose heterocyclique condense et son utilisation medicale |
| US20050043336A1 (en) * | 2001-11-03 | 2005-02-24 | Hennequin Laurent Francois Andre | Quinazoline derivatives as antitumor agents |
| GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
| TWI324597B (en) * | 2002-03-28 | 2010-05-11 | Astrazeneca Ab | Quinazoline derivatives |
| US6924285B2 (en) * | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| GB0309009D0 (en) * | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
| GB0309850D0 (en) * | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
| GB0317665D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
| UY28441A1 (es) * | 2003-07-29 | 2005-02-28 | Astrazeneca Ab | Derivados de quinazolina |
| EP1664028A1 (fr) * | 2003-09-16 | 2006-06-07 | AstraZeneca AB | Dérivés de quinozaline en tant qu'inhibiteurs de la tyrosine kinase |
| AU2004272346A1 (en) * | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives |
| GB0321648D0 (en) * | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
| ATE395346T1 (de) * | 2003-09-16 | 2008-05-15 | Astrazeneca Ab | Chinazolinderivate als tyrosinkinaseinhibitoren |
| CN1882570B (zh) * | 2003-09-19 | 2010-12-08 | 阿斯利康(瑞典)有限公司 | 喹唑啉衍生物 |
| WO2005030757A1 (fr) * | 2003-09-25 | 2005-04-07 | Astrazeneca Ab | Derives de quinazoline |
| GB0322409D0 (en) * | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
| GB0326459D0 (en) * | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| DE602005010824D1 (de) * | 2004-02-03 | 2008-12-18 | Astrazeneca Ab | Chinazolinderivate |
| BRPI0511741A (pt) * | 2004-06-04 | 2008-01-02 | Astrazeneca Ab | derivado de quinazolina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processo para a preparação de um derivado de quinazolina ou de um sal farmaceuticamente aceitável do mesmo |
-
2004
- 2004-09-13 EP EP04768457A patent/EP1664030A1/fr not_active Withdrawn
- 2004-09-13 MX MXPA06003161A patent/MXPA06003161A/es unknown
- 2004-09-13 US US10/572,303 patent/US20080234263A1/en not_active Abandoned
- 2004-09-13 AU AU2004272345A patent/AU2004272345A1/en not_active Abandoned
- 2004-09-13 WO PCT/GB2004/003911 patent/WO2005026156A1/fr not_active Ceased
- 2004-09-13 CA CA002541100A patent/CA2541100A1/fr not_active Abandoned
- 2004-09-14 TW TW093127779A patent/TW200526636A/zh unknown
- 2004-09-16 AR ARP040103320A patent/AR045753A1/es unknown
- 2004-09-16 UY UY28519A patent/UY28519A1/es unknown
-
2006
- 2006-03-19 IL IL174390A patent/IL174390A0/en unknown
- 2006-03-28 NO NO20061415A patent/NO20061415L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004272345A1 (en) | 2005-03-24 |
| CA2541100A1 (fr) | 2005-03-24 |
| US20080234263A1 (en) | 2008-09-25 |
| WO2005026156A1 (fr) | 2005-03-24 |
| TW200526636A (en) | 2005-08-16 |
| MXPA06003161A (es) | 2006-06-05 |
| AR045753A1 (es) | 2005-11-09 |
| EP1664030A1 (fr) | 2006-06-07 |
| IL174390A0 (en) | 2011-08-01 |
| UY28519A1 (es) | 2005-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20061415L (no) | Kinazolinderivater | |
| NO20061327L (no) | Kinazolinderivater | |
| NO20066081L (no) | Kinazolinderivater som erbB-reseptortyrosinkinaser | |
| NO20061743L (no) | Kinazolinderivater | |
| NO20061746L (no) | Kinazolinderivater som antiproliferative midler | |
| NO20060415L (no) | Piperidyl-Kinazolinderivater som Tyrosin-Kinase-Inhibitorer | |
| IS2855B (is) | 4-anilínókínasólínafleiður sem andfjölgunarefni | |
| NO20080675L (no) | P38-Map kinaseinhibitorer og metoder for deres anvendelse | |
| NO20061322L (no) | Kinazolinderivater som tyrosin kinase inhibitorer | |
| NO20061323L (no) | Kinazolinderivater | |
| ATE353888T1 (de) | Chinazolinderivate | |
| NO20090631L (no) | Morpholin pyrimidin derivativer anvendelige i behandlingen av proliferative lidelser | |
| NO20071320L (no) | Pyrazolsubstituerte aminoheteroarylforbindelser som protein kinase inhibitorer. | |
| NO20081893L (no) | 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft | |
| NO20070526L (no) | Kinazolindionderivater som parp-inhibitorer | |
| CY1109681T1 (el) | Υποκατεστημενα παραγωγα κιναζολινης ως αναστολεις των κινασων aurora | |
| NO20070681L (no) | 2, 4, 6-Trisubstituterte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse i behandling av kreft | |
| NO20070655L (no) | 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft | |
| NO20092737L (no) | Substituerte pyrazolo-kinazolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som kinase-inhibitorer | |
| NO20070514L (no) | Pyrrolotriazin kinase inhibitorer | |
| NO20055496L (no) | Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer | |
| PL1899329T3 (pl) | Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych | |
| NO20070557L (no) | Ftalazinderivater som PARP-inhibitorer | |
| TW200512205A (en) | Quinazoline derivatives | |
| NO20070656L (no) | 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |